Cerus Stock – Fundamental Analysis
Fundamental Data & Ratios (Balance sheet update: 3/15/2026)
| Balance Sheet | Total Assets | 221,859,000.00 | ROE | 29.28 % |
| Balance Sheet | Total Equity | 64,965,000.00 | ROA | -7.04 % |
| Cashflow | Capital Expenditures | -2,837,000.00 | P/FCF | 50.10 |
| Cashflow | Free Cash Flow | 8,522,000.00 | – | – |
| Cashflow | Operating Cash Flow | 11,359,000.00 | P/CF | 37.59 |
| Income | Earnings per Share (diluted) | -0.08 | Div. Yield | – |
| Income | Net Income | -15,627,000.00 | P/E | -28.00 |
| Income | Shares Outstanding | 190,594,000.00 | P/B | 6.57 |
| Income | Total Revenue | 206,133,000.00 | P/S | 2.07 |
Ratios calculated on: 10/14/2026
Company Description
Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on the Company´s technology for controlling biological replication, is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. The Company has worldwide rights for its intercepts Blood System for three blood components: platelets, plasma and red blood cells. The INTERCEPT Blood System for platelets, or platelet system, and the INTERCEPT Blood System for plasma, or plasma system, have received Conformite Europeene (CE) marks and are being marketed and sold in a number of countries in Europe, The Commonwealth of Independent States, the Middle East and selected countries in other regions worldwide. The Company sells both the platelet and plasma systems using its direct sales force and through distributors.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.cerus.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more